← Back to Search

NMDA Receptor Antagonist

Hydroxynorketamine for Neuropathic Pain (HNK Trial)

Phase 1 & 2
Waitlist Available
Led By Asokumar Buvanendran, MD
Research Sponsored by Rush University Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
If the subject experiences pain relief they may elect not to take as needed medications
Adult patients (18 to 80 years) with an established diagnosis of chronic (> 3 month) NP of the extremities
Screening 3 weeks
Treatment Varies
Follow Up 35 days
Awards & highlights

HNK Trial Summary

This trial will evaluate the effectiveness and duration of a single infusion of (2R,6R)-HNK on pain, physical function, pain interference, sleep disturbance and quality of life in patients with neuropathic pain.

Who is the study for?
Adults aged 18-80 with chronic neuropathic pain in the extremities, who can read/write English and have a BMI of 18-35 kg/m². Participants should not have widespread pain conditions like fibromyalgia, mental illness, or severe medical issues. They must not be allergic to ketamine, pregnant, or using certain substances prior to drug administration.Check my eligibility
What is being tested?
The trial is testing the effectiveness of (2R,6R)-hydroxynorketamine compared to ketamine and saline for reducing neuropathic pain. Patients will receive each treatment through an infusion over a cross-over design with intervals of five weeks between treatments.See study design
What are the potential side effects?
Potential side effects may include reactions similar to those associated with ketamine such as changes in blood pressure or heart rate, dizziness, nausea, mood changes, blurred vision and possibly dissociation or hallucinations.

HNK Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
I choose not to take pain medication if I feel better.
I am between 18 and 80 years old with chronic nerve pain in my limbs for over 3 months.
I have been diagnosed with neuropathic pain based on a specific questionnaire.
I am on medication for chronic nerve pain and agree to continue it during the study.
My BMI is between 18 and 35, and I weigh between 50 kg and 120 kg.

HNK Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~35 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 35 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Pain intensity
Secondary outcome measures
Analgesic consumption
Pain qualities
PainDETECT questionnaire screening scores

HNK Trial Design

3Treatment groups
Experimental Treatment
Active Control
Placebo Group
Group I: (2R,6R)-hydroxynorketamineExperimental Treatment1 Intervention
(2R,6R)-hydroxynorketamine 0.5mg/kg 45 minute infusion x 1
Group II: KetamineActive Control1 Intervention
Ketamine 0.5mg/kg 45 minute infusion x 1
Group III: SalinePlacebo Group1 Intervention
Saline 45 minute infusion x 1

Find a Location

Who is running the clinical trial?

Rush University Medical CenterLead Sponsor
420 Previous Clinical Trials
163,209 Total Patients Enrolled
Congressionally Directed Medical Research ProgramsFED
47 Previous Clinical Trials
7,024 Total Patients Enrolled
Asokumar Buvanendran, MDPrincipal InvestigatorRush University Medical Center
10 Previous Clinical Trials
1,396 Total Patients Enrolled

Media Library

(2R,6R)-hydroxynorketamine (NMDA Receptor Antagonist) Clinical Trial Eligibility Overview. Trial Name: NCT05864053 — Phase 1 & 2
Neuropathic Pain Research Study Groups: Ketamine, (2R,6R)-hydroxynorketamine, Saline
Neuropathic Pain Clinical Trial 2023: (2R,6R)-hydroxynorketamine Highlights & Side Effects. Trial Name: NCT05864053 — Phase 1 & 2
(2R,6R)-hydroxynorketamine (NMDA Receptor Antagonist) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05864053 — Phase 1 & 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does this research involve adults over the age of 25?

"To be eligible for this medical trial, individuals must not have exceeded 75 years of age and should at least be over 18."

Answered by AI

What criteria must be met for individuals to join this scientific trial?

"Candidates should be aged 18-75 and suffer from neuropathic pain to qualify for the trial. The team is looking for 25 participants in total."

Answered by AI

Are participants still being sought to join this clinical venture?

"Unfortunately, the clinical trial is not presently enrolling patients. Initially posted on January 1st 2024 and last updated May 8th 2023, it has ended its recruitment period; however, there are currently 138 other medical studies actively searching for participants."

Answered by AI
Recent research and studies
~17 spots leftby Dec 2026